UCLA AIDS Prevention and Treatment Clinical Trials Unit

加州大学洛杉矶分校艾滋病预防和治疗临床试验单位（UCLA-APT-CTU）是一个多学科的 研究单位由一个核心行政单位和四个临床研究地点在洛杉矶大都市 洛杉矶。调查小组在设计、实施、 开展临床试验，评估治疗和预防策略。领导下 Judith Currier医学博士，理学硕士和高级研究员团队，包括托马斯科茨博士，罗纳德Mitsuyasu， 医学博士，埃里克达尔，医学博士，凯茜雷贝克，博士，史蒂夫肖普托，博士和斯蒂芬布朗医学博士，该单位将 参与设计和开展针对以下四个优先研究领域的研究; 预防HIV感染、转化研究/药物开发、临床优化 与艾滋病临床试验组合作进行疫苗研究和开发 艾滋病毒预防试验网络（HTPN）和疫苗试验网络（VTN）。反恐组有一个 加州大学洛杉矶分校临床艾滋病研究和教育中心的行政核心和临床研究中心 (CARE中心）和其他临床研究中心（CRS）在海港加州大学洛杉矶分校医学中心和朋友 研究所/综合药物滥用计划（ISAP），加州大学洛杉矶分校和艾滋病研究联盟。的 该股的具体目标是： 1.评估新的和可能更有效的艾滋病毒治疗方法。 2.评估在不同人群中最佳使用抗逆转录病毒疗法（ARV）的策略。 3.评估优化艾滋病毒感染和相关并发症管理的战略。 4.研究用于治疗和预防HIV感染的HIV疫苗。 5.评估预防高危兴奋剂和注射毒品使用者感染艾滋病毒的新策略。 6.评估使用抗逆转录病毒药物预防艾滋病毒感染的策略。 7.评估急性感染者早期干预对长期结果的作用， 传输速率。 8.指导新的少数族裔研究人员进行跨学科艾滋病毒/艾滋病研究。 9.通过参与ACTG，HPTN和VTN的领导做出重大贡献 小组领导、科学委员会和礼宾小组。 10.促进社区参与，鼓励妇女和少数种族/族裔参与 UCLA-APT-CTU的ACTG、HPTN和VTN临床试验。

The UCLA AIDS Prevention and Treatment Clinical Trials Unit (UCLA-APT-CTU) is a multidisciplinary research unit composed of a core administrative unit and four clinical research sites in metropolitan Los Angeles. The investigative team has over 15 years of leadership experience in the design, implementation, and conduct of clinical trials evaluating both therapeutic and prevention strategies. Under the leadership of Judith Currier MD, MSc and a senior investigator team including Thomas Coates, PhD, Ronald Mitsuyasu, MD, Eric Daar, MD, Cathy Reback, Ph D, Steve Shoptaw, PhD and Stephen Brown MD, the unit will participate in the design and conduct of studies addressing the following four priority research areas; Prevention of HIV Infection, Translational Research/Drug Development, Optimization of Clinical Management, and Vaccine Research and Development in collaboration with the AIDS Clinical Trials Group (ACTG), the HIV Prevention Trials Network (HTPN) and the Vaccine Trials Network (VTN). The CTU has an administrative core and clinical research site at the UCLA Center for Clinical AIDS Research and Education (CARE Center) and additional Clinical Research Sites (CRS) at Harbor UCLA Medical Center and Friends Research Institute/Integrated Substance Abuse Program (ISAP) UCLA and AIDS Research Alliance. The specific aims of our unit are to: 1. Evaluate new and potentially more effective HIV treatments. 2. Evaluate strategies for optimal use of antiretroviral therapies (ARV) in diverse populations. 3. Evaluate strategies to optimize the management of HIV infection and related co-morbidities. 4. Investigate HIV vaccines for therapy and for prevention of HIV infection. 5. Evaluate novel strategies for prevention of HIV infection in high-risk stimulant and injection drug users. 6. Evaluate strategies using ARV to prevent HIV acquisition. 7. Assess the role of early interventions in acutely infected individuals on long-term outcomes and transmission rates. 8. Mentor new minority investigators in cross-disciplinary HIV/AIDS research. 9. Make significant contributions to the leadership of the ACTG, HPTN and VTN through participation in the group leadership, scientific committees and protocol teams. 10. Stimulate community involvement and encourage participation of women and racial/ethnic minorities in ACTG, HPTN and VTN clinical trials at the UCLA-APT-CTU.